{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:41:53Z","timestamp":1790401313624,"version":"4.1.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T00:00:00Z","timestamp":1685836800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40263-023-01013-8","type":"journal-article","created":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T14:01:35Z","timestamp":1685887295000},"page":"531-544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-1674","authenticated-orcid":false,"given":"Laurent M.","family":"Willems","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"van der Goten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3134-8697","authenticated-orcid":false,"given":"Felix","family":"von Podewils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6298-0513","authenticated-orcid":false,"given":"Susanne","family":"Knake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2500-6893","authenticated-orcid":false,"given":"Stjepana","family":"Kovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7245-2562","authenticated-orcid":false,"given":"Johann Philipp","family":"Z\u00f6llner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-7471","authenticated-orcid":false,"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9915","authenticated-orcid":false,"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,4]]},"reference":[{"issue":"8","key":"1013_CR1","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00415-017-8394-2","volume":"264","author":"M Manford","year":"2017","unstructured":"Manford M. Recent advances in epilepsy. J Neurol. 2017;264(8):1811\u201324.","journal-title":"J Neurol"},{"issue":"10","key":"1013_CR2","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1093\/brain\/awac234","volume":"145","author":"RJ Piper","year":"2022","unstructured":"Piper RJ, Richardson RM, Worrell G, Carmichael DW, Baldeweg T, Litt B, et\u00a0al. Towards network-guided neuromodulation for epilepsy. Brain. 2022;145(10):3347\u201362.","journal-title":"Brain"},{"issue":"1","key":"1013_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yapd.2022.03.014","volume":"69","author":"V Joris","year":"2022","unstructured":"Joris V, Weil AG, Fallah A. Brain surgery for medically intractable epilepsy. Adv Pediatr. 2022;69(1):59\u201374.","journal-title":"Adv Pediatr"},{"key":"1013_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108666","volume":"130","author":"M Hochbaum","year":"2022","unstructured":"Hochbaum M, Kienitz R, Rosenow F, Schulz J, Habermehl L, Langenbruch L, et\u00a0al. Trends in antiseizure medication prescription patterns among all adults, women, and older adults with epilepsy: a German longitudinal analysis from 2008 to 2020. Epilepsy Behav. 2022;130: 108666.","journal-title":"Epilepsy Behav"},{"issue":"13","key":"1013_CR5","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jama.2022.3880","volume":"327","author":"AM Kanner","year":"2022","unstructured":"Kanner AM, Bicchi MM. Antiseizure medications for adults with epilepsy: a review. JAMA. 2022;327(13):1269\u201381.","journal-title":"JAMA"},{"issue":"1","key":"1013_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/epi.13273","volume":"57","author":"KM Sauro","year":"2016","unstructured":"Sauro KM, Wiebe S, Dunkley C, Janszky J, Kumlien E, Moshe S, et\u00a0al. The current state of epilepsy guidelines: a systematic review. Epilepsia. 2016;57(1):13\u201323.","journal-title":"Epilepsia"},{"issue":"32","key":"1013_CR7","doi-asserted-by":"publisher","first-page":"E1253","DOI":"10.1503\/cmaj.210065","volume":"193","author":"G Moores","year":"2021","unstructured":"Moores G, D\u2019Souza R, Bui E. Antiseizure medications and pregnancy. CMAJ. 2021;193(32):E1253.","journal-title":"CMAJ"},{"issue":"1","key":"1013_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1517\/17425255.2012.645535","volume":"8","author":"SM Jankovic","year":"2012","unstructured":"Jankovic SM, Dostic M. Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects. Expert Opin Drug Metab Toxicol. 2012;8(1):81\u201391.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"1013_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/npr2.12196","volume":"41","author":"T Hakami","year":"2021","unstructured":"Hakami T. Neuropharmacology of antiseizure drugs. Neuropsychopharmacol Rep. 2021;41(3):336\u201351.","journal-title":"Neuropsychopharmacol Rep"},{"issue":"2","key":"1013_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/17460441.2019.1553951","volume":"14","author":"AS Miranda","year":"2019","unstructured":"Miranda AS, Miranda AS, Teixeira AL. Lamotrigine as a mood stabilizer: insights from the pre-clinical evidence. Expert Opin Drug Discov. 2019;14(2):179\u201390.","journal-title":"Expert Opin Drug Discov"},{"issue":"10","key":"1013_CR11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Schubert-Bast S. Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies. CNS Drugs. 2022;36(10):1079\u2013111.","journal-title":"CNS Drugs"},{"key":"1013_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107939","volume":"118","author":"BJ Steinhoff","year":"2021","unstructured":"Steinhoff BJ, Klein P, Klitgaard H, Laloyaux C, Moseley BD, Ricchetti-Masterson K, et\u00a0al. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review. Epilepsy Behav. 2021;118: 107939.","journal-title":"Epilepsy Behav"},{"key":"1013_CR13","doi-asserted-by":"crossref","unstructured":"Mammi A, Ferlazzo E, Gasparini S, Bova V, Neri S, Labate A, et\u00a0al. Psychiatric and behavioural side effects associated with perampanel in patients with temporal lobe epilepsy. a real-world experience. Front Neurol. 2022;13:839985.","DOI":"10.3389\/fneur.2022.839985"},{"key":"1013_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.576579","volume":"11","author":"CQ Zhang","year":"2020","unstructured":"Zhang CQ, He BM, Hu ML, Sun HB. Risk of valproic acid-related tremor: a systematic review and meta-analysis. Front Neurol. 2020;11: 576579.","journal-title":"Front Neurol"},{"issue":"9","key":"1013_CR15","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/jcph.1611","volume":"60","author":"SP Callisto","year":"2020","unstructured":"Callisto SP, Illamola SM, Birnbaum AK, Barkley CM, Bathena SPR, Leppik IE, et\u00a0al. Severity of topiramate-related working memory impairment is modulated by plasma concentration and working memory capacity. J Clin Pharmacol. 2020;60(9):1166\u201376.","journal-title":"J Clin Pharmacol"},{"key":"1013_CR16","doi-asserted-by":"publisher","first-page":"205031211877247","DOI":"10.1177\/2050312118772471","volume":"6","author":"MB Ayalew","year":"2018","unstructured":"Ayalew MB, Muche EA. Patient reported adverse events among epileptic patients taking antiepileptic drugs. SAGE Open Med. 2018;6:2050312118772471.","journal-title":"SAGE Open Med"},{"key":"1013_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.seizure.2019.01.014","volume":"66","author":"M Bosak","year":"2019","unstructured":"Bosak M, Slowik A, Iwanska A, Lipinska M, Turaj W. Co-medication and potential drug interactions among patients with epilepsy. Seizure. 2019;66:47\u201352.","journal-title":"Seizure"},{"key":"1013_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.yebeh.2017.05.022","volume":"73","author":"E Bruun","year":"2017","unstructured":"Bruun E, Virta LJ, Kalviainen R, Keranen T. Co-morbidity and clinically significant interactions between antiepileptic drugs and other drugs in elderly patients with newly diagnosed epilepsy. Epilepsy Behav. 2017;73:71\u20136.","journal-title":"Epilepsy Behav"},{"issue":"5","key":"1013_CR19","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1111\/epi.16500","volume":"61","author":"A Hagemann","year":"2020","unstructured":"Hagemann A, Klimpel D, Bien CG, Brandt C, May TW. Influence of dose and antiepileptic comedication on brivaracetam serum concentrations in patients with epilepsy. Epilepsia. 2020;61(5):e43\u20138.","journal-title":"Epilepsia"},{"issue":"7","key":"1013_CR20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/j.1528-1167.2007.01043.x","volume":"48","author":"LJ Hirsch","year":"2007","unstructured":"Hirsch LJ, Arif H, Buchsbaum R, Weintraub D, Lee J, Chang JT, et\u00a0al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia. 2007;48(7):1351\u20139.","journal-title":"Epilepsia"},{"issue":"5","key":"1013_CR21","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/FTD.0000000000000538","volume":"40","author":"TW May","year":"2018","unstructured":"May TW, Helmer R, Bien CG, Brandt C. Influence of dose and antiepileptic comedication on lacosamide serum concentrations in patients with epilepsy of different ages. Ther Drug Monit. 2018;40(5):620\u20137.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"1013_CR22","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1001\/archneur.62.9.1432","volume":"62","author":"D Weintraub","year":"2005","unstructured":"Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol. 2005;62(9):1432\u20136.","journal-title":"Arch Neurol"},{"key":"1013_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2017.09.013","volume":"77","author":"J Vidaurre","year":"2017","unstructured":"Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol. 2017;77:23\u201336.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"1013_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.seizure.2005.12.009","volume":"15","author":"SN Ahmed","year":"2006","unstructured":"Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure. 2006;15(3):156\u201364.","journal-title":"Seizure"},{"issue":"9","key":"1013_CR25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/17512433.2017.1353418","volume":"10","author":"SA Hamed","year":"2017","unstructured":"Hamed SA. The effect of antiepileptic drugs on the kidney function and structure. Expert Rev Clin Pharmacol. 2017;10(9):993\u20131006.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"1013_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s42466-022-00209-5","volume":"4","author":"K Korbel","year":"2022","unstructured":"K\u00f6rbel K, Rosenow F, Maltseva M, M\u00fcller H, Schulz J, Tsalouchidou PE, et\u00a0al. Impact of COVID-19 pandemic on physical and mental health status and care of adults with epilepsy in Germany. Neurol Res Pract. 2022;4(1):44.","journal-title":"Neurol Res Pract"},{"issue":"6","key":"1013_CR27","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/epi.17229","volume":"63","author":"LM Willems","year":"2022","unstructured":"Willems LM, Hochbaum M, Z\u00f6llner JP, Schulz J, Menzler K, Langenbruch L, et\u00a0al. Trends in resource utilization and cost of illness in patients with active epilepsy in Germany from 2003 to 2020. Epilepsia. 2022;63(6):1591\u2013602.","journal-title":"Epilepsia"},{"key":"1013_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108988","volume":"138","author":"C Mann","year":"2023","unstructured":"Mann C, Maltseva M, von Podewils F, Knake S, Kovac S, Rosenow F, et\u00a0al. Supply problems of antiseizure medication are common among epilepsy patients in Germany. Epilepsy Behav. 2023;138: 108988.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"1013_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1089\/tmj.2022.0238","volume":"29","author":"JP Zollner","year":"2022","unstructured":"Z\u00f6llner JP, Noda AH, McCoy J, Schulz J, Tsalouchidou PE, Langenbruch L, et\u00a0al. Use of health-related apps and telehealth in adults with epilepsy in Germany: a multicenter cohort study. Telemed J E Health. 2022;29(4):540\u201350.","journal-title":"Telemed J E Health"},{"issue":"4","key":"1013_CR30","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/epi.17174","volume":"63","author":"LM Willems","year":"2022","unstructured":"Willems LM, Hochbaum M, Frey K, Schulz J, Menzler K, Langenbruch L, et\u00a0al. Multicenter, cross-sectional study of the costs of illness and cost-driving factors in adult patients with epilepsy. Epilepsia. 2022;63(4):904\u201318.","journal-title":"Epilepsia"},{"issue":"3","key":"1013_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.yebeh.2013.03.007","volume":"27","author":"A Strzelczyk","year":"2013","unstructured":"Strzelczyk A, Haag A, Reese JP, Nickolay T, Oertel WH, Dodel R, et\u00a0al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany. Epilepsy Behav. 2013;27(3):433\u20138.","journal-title":"Epilepsy Behav"},{"issue":"83","key":"1013_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.yebeh.2018.03.025","volume":"9","author":"LM Willems","year":"2018","unstructured":"Willems LM, Richter S, Watermann N, Bauer S, Klein KM, Reese JP, et\u00a0al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013\u2014a ten-year overview. Epilepsy Behav. 2018;9(83):28\u201335.","journal-title":"Epilepsy Behav"},{"issue":"10","key":"1013_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et\u00a0al. The reporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10): e1001885.","journal-title":"PLoS Med"},{"issue":"12","key":"1013_CR34","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E von Elm","year":"2014","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et\u00a0al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495\u20139.","journal-title":"Int J Surg"},{"issue":"3","key":"1013_CR35","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1528-1167.2006.00956.x","volume":"48","author":"RJ Panelli","year":"2007","unstructured":"Panelli RJ, Kilpatrick C, Moore SM, Matkovic Z, D\u2019Souza WJ, O\u2019Brien TJ. The Liverpool Adverse Events Profile: relation to AED use and mood. Epilepsia. 2007;48(3):456\u201363.","journal-title":"Epilepsia"},{"key":"1013_CR36","first-page":"126","volume":"45","author":"RJ Panelli","year":"2004","unstructured":"Panelli RJ, Moore S, Kilpatrick C, Matkovic Z, D\u2019Souza W, O\u2019Brien T. The Liverpool adverse events profile (LAEP) reflects anxiety and depression rather than antiepileptic drug side effects in individual patients. Epilepsia. 2004;45:126.","journal-title":"Epilepsia"},{"key":"1013_CR37","first-page":"S59","volume":"36","author":"GA Baker","year":"1995","unstructured":"Baker GA, Jacoby A, Francis P, Chadwick DW. The Liverpool adverse drug events profile. Epilepsia. 1995;36:S59.","journal-title":"Epilepsia"},{"key":"1013_CR38","doi-asserted-by":"crossref","unstructured":"Vary-O\u2019Neal A, Miranzadeh S, Husein N, Holroyd-Leduc J, Sa\u2019jobi TT, Wiebe S, et\u00a0al. Association between frailty and antiseizure medication tolerability in older adults with epilepsy. Neurology. 2023;100(e1135):e1147.","DOI":"10.1212\/WNL.0000000000201701"},{"issue":"2","key":"1013_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.14581\/jer.18012","volume":"8","author":"OY Kwon","year":"2018","unstructured":"Kwon OY, Park SP. Validity of the liverpool adverse events profile as a screening tool for detecting comorbid depression or anxiety disorder in people with epilepsy. J Epilepsy Res. 2018;8(2):74\u201380.","journal-title":"J Epilepsy Res."},{"issue":"6","key":"1013_CR40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"1013_CR41","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S1474-4422(06)70415-X","volume":"5","author":"FG Gilliam","year":"2006","unstructured":"Gilliam FG, Barry JJ, Hermann BP, Meador KJ, Vahle V, Kanner AM. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol. 2006;5(5):399\u2013405.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1013_CR42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.21315\/mjms2018.25.4.12","volume":"25","author":"MA Bujang","year":"2018","unstructured":"Bujang MA, Sa\u2019at N, Sidik T, Joo LC. Sample size guidelines for logistic regression from observational studies with large population: emphasis on the accuracy between statistics and parameters based on real life clinical data. Malays J Med Sci. 2018;25(4):122\u201330.","journal-title":"Malays J Med Sci"},{"key":"1013_CR43","doi-asserted-by":"crossref","unstructured":"Rogawski MA, L\u00f6scher W, Rho JM. Mechanisms of action of antiseizure drugs and the ketogenic diet. Cold Spring Harb Perspect Med. 2016;6(5).","DOI":"10.1101\/cshperspect.a022780"},{"issue":"9","key":"1013_CR44","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","volume":"35","author":"W Loscher","year":"2021","unstructured":"L\u00f6scher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35(9):935\u201363.","journal-title":"CNS Drugs"},{"key":"1013_CR45","unstructured":"U.S. Food & Drug Administration (FDA). USP therapeutic categories model guidelines. 2018 [cited 2022 15.12.2022]; https:\/\/www.fda.gov\/regulatory-information\/fdaaa-implementation-chart\/usp-therapeutic-categories-model-guidelines. Accessed 15 Dec 2022."},{"issue":"4","key":"1013_CR46","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1590\/1677-5449.174118","volume":"17","author":"HA Miot","year":"2018","unstructured":"Miot HA. Correlation analysis in clinical and experimental studies. J Vasc Bras. 2018;17(4):275\u20139.","journal-title":"J Vasc Bras"},{"key":"1013_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108554","volume":"127","author":"LM Willems","year":"2022","unstructured":"Willems LM, Knake S, Rosenow F, Reese JP, Conradi N, Strzelczyk A. EuroQOL-5D-3L does not adequately map quality-of-life deterioration in severely affected patients with epilepsy. Epilepsy Behav. 2022;127: 108554.","journal-title":"Epilepsy Behav"},{"key":"1013_CR48","volume-title":"Multivariate data analysis using SPSS and AMOS","author":"R Shanthi","year":"2019","unstructured":"Shanthi R. Multivariate data analysis using SPSS and AMOS. Chennai: MJP Publisher; 2019."},{"issue":"1","key":"1013_CR49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0958-1669(02)00288-4","volume":"13","author":"JS Almeida","year":"2002","unstructured":"Almeida JS. Predictive non-linear modeling of complex data by artificial neural networks. Curr Opin Biotechnol. 2002;13(1):72\u20136.","journal-title":"Curr Opin Biotechnol"},{"issue":"1","key":"1013_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0893-6080(88)90021-4","volume":"1","author":"S Grossberg","year":"1988","unstructured":"Grossberg S. Nonlinear neural networks: principles, mechanisms, and architectures. Neural Netw. 1988;1(1):17\u201361.","journal-title":"Neural Netw"},{"key":"1013_CR51","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00521-014-1573-5","volume":"25","author":"J De Ona","year":"2014","unstructured":"De Ona J, Garrido C. Extracting the contribution of independent variables in neural network models: a new approach to handle instability. Neural Comput Appl. 2014;25:859\u201369.","journal-title":"Neural Comput Appl"},{"key":"1013_CR52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.seizure.2020.09.026","volume":"83","author":"E Santamarina","year":"2020","unstructured":"Santamarina E, Bertol V, Garayoa V, Garcia-Gomara MJ, Garamendi-Ruiz I, Giner P, et\u00a0al. Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs. Seizure. 2020;83:48\u201356.","journal-title":"Seizure"},{"issue":"4","key":"1013_CR53","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s00415-021-10751-y","volume":"269","author":"V Villanueva","year":"2022","unstructured":"Villanueva V, D\u2019Souza W, Goji H, Kim DW, Liguori C, McMurray R, et\u00a0al. PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice. J Neurol. 2022;269(4):1957\u201377.","journal-title":"J Neurol"},{"key":"1013_CR54","unstructured":"D\u2019Souza W, Trinka E, Wu T, Najm I, Malhotrea M, Ngo LY, et al. Effectiveness and tolerability of perampanel in epilepsy patients treated in routine clinical practice: a global pooled analysis study (1640). Neurology. 2021;96 (15 Supplement) 1640."},{"issue":"4","key":"1013_CR55","first-page":"215","volume":"32","author":"S Juhl","year":"2017","unstructured":"Juhl S, Rubboli G. Add-on perampanel and aggressive behaviour in severe drug-resistant focal epilepsies. Funct Neurol. 2017;32(4):215\u201320.","journal-title":"Funct Neurol"},{"key":"1013_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106658","volume":"102","author":"SA Lee","year":"2020","unstructured":"Lee SA, Jeon JY, Kim HW. Effect of perampanel on aggression in patients with refractory focal epilepsy: a 6-month longitudinal study. Epilepsy Behav. 2020;102: 106658.","journal-title":"Epilepsy Behav"},{"issue":"8","key":"1013_CR57","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/ene.12170","volume":"20","author":"G Zaccara","year":"2013","unstructured":"Zaccara G, Giovannelli F, Cincotta M, Verrotti A, Grillo E. The adverse event profile of perampanel: meta-analysis of randomized controlled trials. Eur J Neurol. 2013;20(8):1204\u201311.","journal-title":"Eur J Neurol"},{"key":"1013_CR58","doi-asserted-by":"publisher","first-page":"1120150","DOI":"10.3389\/fneur.2023.1120150","volume":"14","author":"C Liguori","year":"2023","unstructured":"Liguori C, Santamarina E, Strzelczyk A, Rodriguez-Uranga JJ, Shankar R, Rodriguez-Osorio X, et\u00a0al. Perampanel outcomes at different stages of treatment in people with focal and generalized epilepsy treated in clinical practice: evidence from the PERMIT study. Front Neurol. 2023;14:1120150.","journal-title":"Front Neurol"},{"issue":"Suppl 1","key":"1013_CR59","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/epi.12504","volume":"55","author":"F Rugg-Gunn","year":"2014","unstructured":"Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia. 2014;55(Suppl 1):13\u20135.","journal-title":"Epilepsia"},{"key":"1013_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/ane.12102","volume":"197","author":"JM Serratosa","year":"2013","unstructured":"Serratosa JM, Villanueva V, Kerling F, Kasper BS. Safety and tolerability of perampanel: a review of clinical trial data. Acta Neurol Scand Suppl. 2013;197:30\u20135.","journal-title":"Acta Neurol Scand Suppl"},{"key":"1013_CR61","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.yebeh.2015.03.005","volume":"46","author":"SK Kim","year":"2015","unstructured":"Kim SK, Park SP, Kwon OY. Impact of depression and anxiety on adverse event profiles in Korean people with epilepsy. Epilepsy Behav. 2015;46:185\u201391.","journal-title":"Epilepsy Behav"},{"issue":"9","key":"1013_CR62","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.seizure.2014.06.007","volume":"23","author":"SJ Lee","year":"2014","unstructured":"Lee SJ, Kim JE, Seo JG, Cho YW, Lee JJ, Moon HJ, et\u00a0al. Predictors of quality of life and their interrelations in Korean people with epilepsy: a MEPSY study. Seizure. 2014;23(9):762\u20138.","journal-title":"Seizure"},{"key":"1013_CR63","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.yebeh.2017.07.016","volume":"75","author":"JA Micoulaud-Franchi","year":"2017","unstructured":"Micoulaud-Franchi JA, Bartolomei F, Duncan R, McGonigal A. Evaluating quality of life in epilepsy: the role of screening for adverse drug effects, depression, and anxiety. Epilepsy Behav. 2017;75:18\u201324.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1013_CR64","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3325\/cmj.2018.59.13","volume":"59","author":"M Lovric","year":"2018","unstructured":"Lovric M, Cajic I, Petelin Gadze Z, Klarica Domjanovic I, Bozina N. Effect of antiepileptic drug comedication on lamotrigine concentrations. Croat Med J. 2018;59(1):13\u20139.","journal-title":"Croat Med J"},{"key":"1013_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.938552","volume":"13","author":"E Jeong","year":"2022","unstructured":"Jeong E, Nelson SD, Su Y, Malin B, Li L, Chen Y. Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system. Front Pharmacol. 2022;13: 938552.","journal-title":"Front Pharmacol"},{"issue":"9","key":"1013_CR66","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40262-022-01152-z","volume":"61","author":"M Wanounou","year":"2022","unstructured":"Wanounou M, Caraco Y, Levy RH, Bialer M, Perucca E. Clinically relevant interactions between ritonavir-boosted nirmatrelvir and concomitant antiseizure medications: implications for the management of COVID-19 in patients with epilepsy. Clin Pharmacokinet. 2022;61(9):1219\u201336.","journal-title":"Clin Pharmacokinet"},{"issue":"10282","key":"1013_CR67","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","volume":"397","author":"A Marson","year":"2021","unstructured":"Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et\u00a0al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1375\u201386.","journal-title":"Lancet"},{"key":"1013_CR68","first-page":"CD014701","volume":"2021","author":"M Gianatsi","year":"2021","unstructured":"Gianatsi M, Bresnahan R, Hill RA, Nevitt SJ, Marson AG, Tudur-Smith C. Valproate add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2021;2021:CD014701.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1013_CR69","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4103\/ijt.ijt_10_18","volume":"10","author":"A Kakunje","year":"2018","unstructured":"Kakunje A, Prabhu A, Sindhu Priya ES, Karkal R, Kumar P, Gupta N, et\u00a0al. Valproate: it\u2019s effects on hair. Int J Trichol. 2018;10(4):150\u20133.","journal-title":"Int J Trichol"},{"issue":"1","key":"1013_CR70","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/s41598-017-02525-2","volume":"7","author":"C Zhuo","year":"2017","unstructured":"Zhuo C, Jiang R, Li G, Shao M, Chen C, Chen G, et\u00a0al. Efficacy and tolerability of second and third generation anti-epileptic drugs in refractory epilepsy: a network meta-analysis. Sci Rep. 2017;7(1):2535.","journal-title":"Sci Rep"},{"key":"1013_CR71","doi-asserted-by":"publisher","first-page":"175628642110374","DOI":"10.1177\/17562864211037430","volume":"14","author":"T Hakami","year":"2021","unstructured":"Hakami T. Efficacy and tolerability of antiseizure drugs. Ther Adv Neurol Disord. 2021;14:17562864211037430.","journal-title":"Ther Adv Neurol Disord"},{"key":"1013_CR72","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/OPTH.S27695","volume":"6","author":"MA Abtahi","year":"2012","unstructured":"Abtahi MA, Abtahi SH, Fazel F, Roomizadeh P, Etemadifar M, Jenab K, et\u00a0al. Topiramate and the vision: a systematic review. Clin Ophthalmol. 2012;6:117\u201331.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"1013_CR73","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/CIA.S3785","volume":"26","author":"BR Sommer","year":"2010","unstructured":"Sommer BR, Fenn HH. Review of topiramate for the treatment of epilepsy in elderly patients. Clin Interv Aging. 2010;26(5):89\u201399.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"1013_CR74","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000477742","volume":"4","author":"Y Bello-Hernandez","year":"2018","unstructured":"Bello-Hernandez Y, Espinoza-Hernandez J, Moreno-Coutino G. Acneiform rash caused by an unlikely drug: topiramate. Skin Append Disord. 2018;4(1):25\u20138.","journal-title":"Skin Append Disord"},{"issue":"4","key":"1013_CR75","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4103\/0019-5154.84746","volume":"56","author":"A Aggarwal","year":"2011","unstructured":"Aggarwal A, Kumar R, Sharma RC, Sharma DD. Topiramate induced pruritus in a patient with alcohol dependence. Indian J Dermatol. 2011;56(4):421\u20132.","journal-title":"Indian J Dermatol"},{"issue":"10","key":"1013_CR76","first-page":"CD001417","volume":"10","author":"R Bresnahan","year":"2019","unstructured":"Bresnahan R, Hounsome J, Jette N, Hutton JL, Marson AG. Topiramate add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2019;10(10):CD001417.","journal-title":"Cochrane Database Syst Rev"},{"key":"1013_CR77","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ebcr.2014.04.002","volume":"2","author":"A Romigi","year":"2014","unstructured":"Romigi A, Vitrani G, D\u2019Aniello A, Di Gennaro G. Topiramate-induced periodic limb movement disorder in a patient affected by focal epilepsy. Epilepsy Behav Case Rep. 2014;2:121\u20133.","journal-title":"Epilepsy Behav Case Rep"},{"issue":"2","key":"1013_CR78","doi-asserted-by":"publisher","first-page":"197","DOI":"10.5664\/jcsm.1782","volume":"8","author":"T Mathew","year":"2012","unstructured":"Mathew T, Sarma GR, Nadig R, Varghese R. Topiramate-induced somnambulism in a migraineur: a probable idiosyncratic adverse effect. J Clin Sleep Med. 2012;8(2):197\u20138.","journal-title":"J Clin Sleep Med"},{"issue":"4","key":"1013_CR79","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3988\/jcn.2007.3.4.175","volume":"3","author":"SP Park","year":"2007","unstructured":"Park SP, Kim SY, Hwang YH, Lee HW, Suh CK, Kwon SH. Long-term efficacy and safety of zonisamide monotherapy in epilepsy patients. J Clin Neurol. 2007;3(4):175\u201380.","journal-title":"J Clin Neurol"},{"issue":"7\u20138","key":"1013_CR80","doi-asserted-by":"publisher","first-page":"397","DOI":"10.5177\/ntvt.2018.07\/08.18123","volume":"125","author":"C de Baat","year":"2018","unstructured":"de Baat C, Zweers P, Vissink A. Medicaments and oral healthcare. Proliferation of the gingiva. Ned Tijdschr Tandheelkd. 2018;125(7\u20138):397\u2013402.","journal-title":"Ned Tijdschr Tandheelkd"},{"issue":"6","key":"1013_CR81","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1756285611417920","volume":"4","author":"CM Eddy","year":"2011","unstructured":"Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011;4(6):385\u2013407.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"1013_CR82","doi-asserted-by":"publisher","first-page":"518","DOI":"10.2174\/1570159X18666200124145743","volume":"18","author":"H Alonso-Navarro","year":"2020","unstructured":"Alonso-Navarro H, Garcia-Martin E, Agundez JAG, Jimenez-Jimenez FJ. Current and future neuropharmacological options for the treatment of essential tremor. Curr Neuropharmacol. 2020;18(6):518\u201337.","journal-title":"Curr Neuropharmacol"},{"key":"1013_CR83","doi-asserted-by":"crossref","unstructured":"Kienitz R, Kay L, Beuchat I, Gelhard S, von Brauchitsch S, Mann C, et al. Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability. CNS Drugs. 2022;36(9):951\u201375.","DOI":"10.1007\/s40263-022-00940-2"},{"issue":"10","key":"1013_CR84","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/14740338.2018.1518427","volume":"17","author":"R Moavero","year":"2018","unstructured":"Moavero R, Pisani LR, Pisani F, Curatolo P. Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy. Expert Opin Drug Saf. 2018;17(10):1015\u201328.","journal-title":"Expert Opin Drug Saf"},{"key":"1013_CR85","doi-asserted-by":"crossref","unstructured":"Willems LM, Z\u00f6llner JP, Paule E, Schubert-Bast S, Rosenow F, Strzelczyk A. Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence. Expert Rev Clin Pharmacol. 2018;11(3):309\u201324.","DOI":"10.1080\/17512433.2018.1421066"},{"key":"1013_CR86","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.seizure.2018.07.017","volume":"61","author":"M Hirsch","year":"2018","unstructured":"Hirsch M, Hintz M, Specht A, Schulze-Bonhage A. Tolerability, efficacy and retention rate of brivaracetam in patients previously treated with levetiracetam: a monocenter retrospective outcome analysis. Seizure. 2018;61:98\u2013103.","journal-title":"Seizure"},{"key":"1013_CR87","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.seizure.2017.03.010","volume":"48","author":"BJ Steinhoff","year":"2017","unstructured":"Steinhoff BJ, Bacher M, Bucurenciu I, Hillenbrand B, Intravooth T, Kornmeier R, et\u00a0al. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy\u2014a monocenter survey. Seizure. 2017;48:11\u20134.","journal-title":"Seizure"},{"issue":"7","key":"1013_CR88","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/epi.13768","volume":"58","author":"I Steinig","year":"2017","unstructured":"Steinig I, von Podewils F, M\u00f6ddel G, Bauer S, Klein KM, Paule E, et\u00a0al. Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany. Epilepsia. 2017;58(7):1208\u201316.","journal-title":"Epilepsia"},{"key":"1013_CR89","first-page":"9","volume":"23","author":"LM Willems","year":"2018","unstructured":"Willems LM, Bertsche A, B\u00f6sebeck F, Hornemann F, Immisch I, Klein KM, et\u00a0al. Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany. Front Neurol. 2018;23:9.","journal-title":"Front Neurol"},{"issue":"12","key":"1013_CR90","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1111\/epi.17087","volume":"62","author":"A Strzelczyk","year":"2021","unstructured":"Strzelczyk A, Zaveta C, von Podewils F, M\u00f6ddel G, Langenbruch L, Kovac S, et\u00a0al. Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: a longitudinal multicenter study with up to 5 years of follow-up. Epilepsia. 2021;62(12):2994\u20133004.","journal-title":"Epilepsia"},{"issue":"Pt A","key":"1013_CR91","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","volume":"52","author":"SL Yates","year":"2015","unstructured":"Yates SL, Fakhoury T, Liang W, Eckhardt K, Borghs S, D\u2019Souza J. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52(Pt A):165\u20138.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"1013_CR92","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1620\/tjem.248.273","volume":"248","author":"A Kovacs","year":"2019","unstructured":"Kovacs A, Farkas Z, Kelemen A, Juhos V, Szucs A, Kamondi A. Lamotrigine induces tremor among epilepsy patients probably via cerebellar pathways. Tohoku J Exp Med. 2019;248(4):273\u201384.","journal-title":"Tohoku J Exp Med"},{"issue":"2","key":"1013_CR93","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1006\/ebeh.2001.0168","volume":"2","author":"AP Aldenkamp","year":"2001","unstructured":"Aldenkamp AP, Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav. 2001;2(2):85\u201391.","journal-title":"Epilepsy Behav"},{"issue":"9","key":"1013_CR94","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1212\/WNL.56.9.1177","volume":"56","author":"KJ Meador","year":"2001","unstructured":"Meador KJ, Loring DW, Ray PG, Murro AM, King DW, Perrine KR, et\u00a0al. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology. 2001;56(9):1177\u201382.","journal-title":"Neurology"},{"issue":"4","key":"1013_CR95","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40615-015-0101-3","volume":"2","author":"A Baehr","year":"2015","unstructured":"Baehr A, Pena JC, Hu DJ. Racial and ethnic disparities in adverse drug events: a systematic review of the literature. J Racial Ethn Health Dispar. 2015;2(4):527\u201336.","journal-title":"J Racial Ethn Health Dispar"},{"key":"1013_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107483","volume":"112","author":"LM Willems","year":"2020","unstructured":"Willems LM, Balcik Y, Noda AH, Siebenbrodt K, Leimeister S, McCoy J, et\u00a0al. SARS-CoV-2-related rapid reorganization of an epilepsy outpatient clinic from personal appointments to telemedicine services: a German single-center experience. Epilepsy Behav. 2020;112: 107483.","journal-title":"Epilepsy Behav"},{"issue":"5","key":"1013_CR97","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"issue":"Pt A","key":"1013_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106856","volume":"104","author":"JM Welton","year":"2020","unstructured":"Welton JM, Walker C, Riney K, Ng A, Todd L, D\u2019Souza WJ. Quality of life and its association with comorbidities and adverse events from antiepileptic medications: online survey of patients with epilepsy in Australia. Epilepsy Behav. 2020;104(Pt A): 106856.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1013_CR99","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/epi.16763","volume":"62","author":"S Beniczky","year":"2021","unstructured":"Beniczky S, Rampp S, Asadi-Pooya AA, Rubboli G, Perucca E, Sperling MR. Optimal choice of antiseizure medication: agreement among experts and validation of a web-based decision support application. Epilepsia. 2021;62(1):220\u20137.","journal-title":"Epilepsia"},{"issue":"4","key":"1013_CR100","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3988\/jcn.2020.16.4.547","volume":"16","author":"H Kim","year":"2020","unstructured":"Kim H, Kim DW, Lee ST, Byun JI, Seo JG, No YJ, et\u00a0al. Antiepileptic drug selection according to seizure type in adult patients with epilepsy. J Clin Neurol. 2020;16(4):547\u201355.","journal-title":"J Clin Neurol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01013-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01013-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01013-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T15:43:08Z","timestamp":1729525388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01013-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1013"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01013-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"11 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. This study was supported by the State of Hesse under the CEPTER LOEWE Grant for the Center of Personalized Translational Epilepsy Research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"F. von Podewils reports personal fees from UCB Pharma, Arvelle Therapeutics\/Angelini Pharma, Desitin Arzneimittel, Zogenix, Eisai, and GW\/Jazz Pharmaceuticals and grants from the State of Mecklenburg-Vorpommern and the Deutsches Zentrum f\u00fcr Luft- und Raumfahrt (DLR). S. Knake reports personal fees and grants from Angelini Pharma, Bial, Desitin Arzneimittel, Epilog, Kanso, UCB Pharma, UNEEG, and Zogenix. S. Kovac reports grants from Biogen and speakers honoraria from Eisai and Jazz Pharmaceuticals. J. P. Z\u00f6llner reports personal fees from Jazz Pharmaceuticals. F. Rosenow reports grants and personal fees from Roche Pharma, UCB Pharma, Arvelle Therapeutics, and Desitin Arzneimittel, personal fees from Eisai, GW Pharmaceuticals, Novartis, Medtronic, Cerbomed, Sandoz, BayerVital, and Shire and grants from the European Union, Deutsche Forschungsgemeinschaft, the LOEWE Programme of the State of Hesse, and the Detlev\u2013Wrobel\u2013Fonds for Epilepsy Research. A. Strzelczyk reports personal fees and grants from Angelini Pharma, Biocodex,\u00a0Desitin Arzneimittel, Eisai, Jazz (GW) Pharmaceuticals, Marinus Pharmaceuticals, Medtronic, Takeda,\u00a0UCB Pharma (Zogenix), and UNEEG. All other authors report no competing interests. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript apart from those disclosed. There is no funding to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Ethics Advisory Board of Goethe University (Frankfurt am Main, Germany) before its conduction (reference number 19-440).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Study participation was voluntary. Subjects were only enrolled after written informed consent had been obtained.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"A. Strzelczyk conceived the idea for the initial trial and was responsible for the survey. L.M. Willems developed the idea for this analysis. F. von Podewils, S. Knake, S. Kovac, J. P. Z\u00f6llner, F. Rosenow\u00a0and A. Strzelczyk collected the data. M. van den Goten and L.M. Willems processed the data and performed the statistical analyses. L. M. Willems,\u00a0M. van den Goten, J.P. Z\u00f6llner, and A. Strzelczyk drafted the initial manuscript. All authors wrote, edited, and significantly contributed to the final manuscript. All authors approved the final manuscript for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}